Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 20, 2017
Grant Date -
Jul 23, 2015
app pub date -
Aug 7, 2013
filing date -
Aug 13, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to IFN-α fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-α protein. The IFN-α fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-α fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-α fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully